Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss ... 50% by a factor of more than 2 to 1. One other stock from the same industry, Crinetics Pharmaceuticals, Inc. (CRNX), is yet to ...
Zacks.com on MSN16d
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock DownSage Therapeutics, Inc. SAGE reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus ...
Sage Therapeutics ... Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback